
Centers of Excellence in Specialty Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5.
Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.
4.
Gilteritinib (Xospata) was superior to standard chemotherapy in improving overall survival in patients with acute myeloid leukemia.
3.
Immune Globulin Intravenous, Human — slra 10% Liquid (Asceniv) is indicated for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents.
2.
Although lung cancer screenings are covered at no cost by most insurers, state Medicaid programs are not required to offer coverage for this service.
1.
Specialty pharmacy can benefit from having definitive a center of excellence model that caters to respective therapies and disease states.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.














































































































































































































